-> Child Labor & Education
-> Grow Trees
-> Re- Think
-> Reduce your Trash
-> Save Energy Save Electricity
-> Save paper Save trees
-> Save water save life
-> Things one must know
We appreciate your feedback, and will have great regard for the same.
Browser not compatible.
VIVAN Life Sciences Pvt. Limited.
511, Lodha Supremus,
Rd.No.22, Wagle Industrial Estate,
Thane-W, Mumbai - 400604,
Ph. : +91(22) 2587 0080/81/82
Fax : +91(22) 2587 0084
Website : http://www.vivanls.com
e Mail : email@example.com
$10 billion for Development Projects in India
The Asian Development Bank (ADB) today committed USD 10 billion support for infrastructure building and immediate development needs of less-developed states in the country.
Scietists find new method to fight Malaria
Scientists have discovered a new way to slow down malaria infections, providing a possible new target for antimalarial drugs. The team are already working with pharmaceutical companies to use this knowledge to develop new antimalarials -- an important step in the battle against drug resistant malaria.
'one campus one approval' policy by PCI
The pharmacy colleges in the country will no longer need to apply for different educational programmes separately, as the Pharmacy Council of India (PCI) is coming out with 'one campus one approval' policy with the benefit of getting one approval for all the programmes in a particular college.
In the next 6 months, 1000 people to be hired in Benguluru by Omega Healthcare
Omega Healthcare Management Services, a leading technology-driven outsourcing services provider is going to hire 1,000 people in the next 6 months in Bengaluru.
Pharmac South 2017 to be inaugurated by Dr J Radhakrishnan
Pharmac South 2017, the third edition of the south Indian trade show will be held from July 7 to 8 at Chennai Trade Centre.The event will be inaugurated by Dr J Radhakrishnan, Principal Secretary, department of health, government of Tamil Nadu.
NIPER ties up with J&J
NIPER Ahmedabad ties up with J&J to integrate industry practices in medical devices curriculum
New technical services labs in Delhi by Colorcon
Colorcon Inc. announces the opening of a new technical service laboratory and conference facility in Noida, Delhi
Cancer Treatment-Researchers develop new Test
UK-based scientists have developed a new three-in-one blood test able to identify the patients with advanced prostate cancer most likely to benefit from PARP inhibitors, with the potential to ‘transform’ treatment of the disease.
Health ministry appoints agency
Health ministry has appointed agency and awarded it the contract to procure equipment for setting up mini drug testing labs at JNPT, Nhava Sheva and Mumbai Airport to enhance capability for detecting spurious medicines exported from and imported into the country.
New data by AstraZeneca
AstraZeneca presents new data underpinning safety profile and real-world CV outcomes of Farxiga at ADA 2017
Qiagen receives U.S. FDA approval
Qiagen has announced it has received premarket approval from the US Food and Drug Administration (FDA) for cytomegalovirus testing on automated QIAsymphony platform
Cipla gets favourable ruling from DoP
The Indian pharmaceutical major Cipla Ltd has has received favourable ruling from the Department of Pharmaceuticals (DoP) on its three formulations
Mixed response to GST rate
The much-awaited GST rate approved by the GST Council to pave the way for implementation of the new tax regime has invoked mixed response from pharmaceutical industry and trade body.
Dr Reddy's Labs receives US FDA approval
Dr Reddy’s Laboratories Ltd. has received approval from the US Food and Drug Administration (FDA) to launch doxorubicin hydrochloride liposome injection,or intravenous use, in the United States market.
Skin Bank to be launched by Masina Hospital, Mumbai
Mumbai based Masina Hospital has announced that it will soon launch a Skin Bank which will give relatives of burn victims an opportunity to donate skin along with eyes.
GE partners with USAID for India's Healthcare needs
GE Healthcare and the USAID-supported project ‘PAHAL’ (Partnerships for Affordable Health Access & Longevity) announced today their strategic partnership to address the healthcare needs of underserved communities in India.
Telangana-‘Bulk drug manufacturing hub of India'
The Telangana state government is pulling up all the stops to strengthen its bulk drug manufacturing tag and wants to maintain its pioneer status as India’s leading bulk drug manufacturing hub.
Amgen launches online media resource
Amgen announced the launch of Neulasta (pegfilgrastim) Onpro NARRATIVES, an online media resource about the value of a cancer care team that provides comprehensive support for patients receiving strong chemotherapy.
Allergan collaborates with Novartis
Allergan, a leading global biopharmaceutical company, has entered into a clinical trial agreement with Novartis to conduct a phase 2b study, using Allergan's cenicriviroc (CVC) and Novartis' lead FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Phagelux collaborates with Johnson & Johnson
Phagelux collaborates with Johnson & Johnson Innovation to develop skin care products
Survey brings FMCG as the highest paying industry
Pharma and healthcare, offering an average annual CTC of Rs. 8.8 lakh, and telecom (at Rs. 8.7 lakh) take the fourth and fifth position in the list as India's most lucrative industries, the study noted.
Cipla bets on respiratory, oncology and HIV segments in Brazil and China
It is well known in the pharmaceutical industry globally that outside the US and Europe (and India, off course), the best markets for generics business are Brazil, China, Mexico, Turkey and Japan.
Cipla receives final approval for generic Epzicom tablets
Cipla Ltd, a global pharmaceutical company, has received final approval for its Abbreviated New Drug Application (ANDA) for Abacavir and Lamivudine tablets USP, 600 mg/300 mg, from the United States Food and Drug Administration (FDA).
India & Netherlands to begin a Research
The Department of Biotechnology (DBT), India and the Netherlands Organisation for Scientific Research (NWO)/the Netherlands Organisation for Health Research and Development (ZonMw) will soon jointly begin research on 'Technology for a sustainable healthcare: Minimally invasive techniques'.
Abbott to make India hub of global research and development for branded generics
The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor treatment for adults with type 2 diabetes. This new combination agent is to be used alongside diet and exercise in those without adequate blood sugar control with dapagliflozin or who are already treated with dapagliflozin (Farxiga) and saxagliptin (Onglyza). FDA approved Qtern based on data from a trial looking at efficacy and safety of saxagliptin added to dapagliflozin in patients with inadequate control on metformin. Read More
Alembic Pharma's partner launches drug for depressive disorder
Drug firm Alembic PharmaceuticalsBSE 0.88 % today said its partner Breckenridge Pharma has launched desvenlafaxine succinate extended release tablets used in treatment of major depressive disorder. ...........................................
Boehringer signs COPD research deal with Weill
Boehringer Ingelheim and Weill Cornell Medicine are working together to identify novel treatment approaches that could halt or even reverse lung tissue damage in coronary obstructive pulmonary disorder ...........................................
Project Nanhi Kali at the Standard Chartered Mumbai Marathon, 2017
Project Nanhi Kali (PNK) once again had a great turn out at the Standard Chartered Mumbai Marathon held on Sunday, Jan 15, 2017...........................................
Pharm-Olam nabs PE investment amid 'market void' for mid-tier CROs
Pharm-Olam has secured an investment from Quad-C Management as the private equity firm eyes add-on acquisitions to complement organic growth....................................
US FDA accepts Intarcia's NDA for ITCA 650 to treat type 2 diabetes
International + Font Resize - US FDA accepts Intarcia's NDA for ITCA 650 to treat type 2 diabetes Boston, Massachusetts Tuesday, February 07, 2017, 17:00 Hrs [IST] Intarcia Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted for active review its New Drug Application (NDA) for ITCA 650, an investigational therapy for the treatment of type 2 diabetes (T2D). Intarcia looks forward to working closely with the FDA through the review process...................................
Almac launches temperature management software
Almac Group has launched a GDP-compliant web-based platform, TempEZ, to provide customers with a single database to store temperature data from the manufacturing stage to patient administration..................................
GMP-status 'a major step' for medical marijuana recognition, Bedrocan
The GMP certification of a Dutch cannabis production facility is a “major step” in bringing medicinal marijuana to the level of evidence based medicines, says Bedrocan.................................
Trump names chair of vaccine commission to examine 'scientific integrity';
President-elect Donald Trump has asked noted vaccine skeptic Robert F. Kennedy Jr. to chair a commission to investigate vaccine safety................................
Bayer's regorafenib receives US FDA Priority Review status for second-line treatment of liver cancer;
The US Food and Drug Administration (FDA) has granted priority review designation to Bayer's supplemental New Drug Application (sNDA) for regorafenib for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in the US...............................
Indian pharma industry facing growth headwinds;
Indian pharmaceutical industry will grow at a slower pace due to sluggish growth in the US market, increased competition leading to price erosion in high single digits and generic adoption reaching saturation levels, rating agency ICRA said today..........................
Parker Institute, Cancer Research Institute team up on neoantigen-based cancer vaccines;
Researchers at 30 prestigious groups are coming together under a collaboration between the legacy Cancer Research Institute and tech billionaire Sean Parker’s new Parker Institute for Cancer Immunotherapy. Their goal? To advance development of personalized cancer vaccines based on neoantigens.........................
Greater efforts are needed to encourage patients to report adverse drug reactions;
In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of reporting systems and others were confused about reporting........................
Lupin launches Amabelz tablets in US market;
The company's product is indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.......................
FDA to crack whip on pharma companies;
The Food and Drug Administration (FDA), Nashik has decided to go tough on pharmaceutical companies.......................
Eisai kicks off mid-stage study of sleep drug;
ISWRD is a circadian rhythm sleep disorder characterised by an irregular sleep-wake pattern, with patients experiencing multiple naps during the daytime but then fragmented and shortened sleep during the night.......................
Using the freshest blood for transfusions does not appear to boost patient survival, a new Canadian study indicates.;
Old Blood as Good as New for Transfusions, Study Finds......................
FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma;
The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS)......................
Chinese API makers look to move up the value chain;
China’s pharma industry is best known for being the low-cost generic API producer to the world. But companies there, large and small, are looking for ways to move up the value chain, including doing deals targeted at the U.S. market...................
Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II;
Just months after signing on with the Walter Reed Army Institute of Research to develop a Zika vaccine, Sanofi Pasteur won a $43 million vote of confidence from the U.S. government’s BARDA to advance the work..................
Power Grid, Pidilite, Bharat Financial, Aurobindo Pharma.;
The stock has given a fresh breakout on daily, weekly and monthly chart as managed to hit its record life time high levels.................
Now, a paper-based device can spot poor-quality medicines;
Scientists have developed a simple, inexpensive paper-based device which can identify poor-quality or degraded medications within minutes.................
HarlePhil Ventures to market Biocept's liquid biopsy tests in Philippines;
Biocept, Inc, a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announced a preferred provider agreement with HarlePhil Ventures, Inc.,..............
Cipla appoints Kedar Upadhye as global CFO;
Cipla Ltd, a global pharmaceutical company, has announced the appointment of Kedar Upadhye as the global chief financial officer of the company effective August 1, 2016..............
FMC elects current director as new vice president >
PHILADELPHIA, US: FMC Corporation (FMC) said that it has elected Amy O'Shea, recently appointed as business director for North America Crop for FMC Agricultural Solutions as its vice president of FMC..............
GlobalData expects IPF market to more than treble to $3.2bn by 2025 >
Research and consulting firm GlobalData expects that the idiopathic pulmonary fibrosis (IPF) market will increase to $3.2bn by 2025 from just more than $900m in 2015.............
Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, >
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS............
Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients;
Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine)............
Keytruda, developed by Schering Plough / Merck and Co, and Opdivo, developed by Ono / Bristol-Myers Squibb, are estimated to account for 50% of the global immuno-oncology market by 2024, estimates a report from GlobalData.........
GlaxoSmithKline (GSK) has agreed to acquire Bristol-Myers Squibb's (BMS) pipeline of research and development (R&D) HIV assetsfor about $1.5bn;
Teva wins approval for COPAXONE to prevent relapse of multiple sclerosis............
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Teva Pharmaceutical Industries' once-daily COPAXONE (glatiramer acetate injection) 20mg injection for the prevention of relapse of multiple sclerosis;
rs Squibb's HIV assets............
Bristol-Myers Squibb announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection;
Jubilant Life Sciences wins ANDA approval for Rizatriptan Benzoate OD Tablets............
FDA approves Merrimack’s metastatic pancreatic cancer drug............
The US Food and Drug Administration (FDA) has approved Merrimack Pharmaceuticals’ metastatic pancreatic cancer drug, Onivyde;
UK launches largest trial to assess whether aspirin can fight cancer............
The world's largest clinical trial to see whether taking a daily dose of aspirin can stop cancer from recurring has been launched in the UK;
Pfizer-Allergan megamerger report prompts speculation about fallout for CROs............
Reports Pfizer is considering buying Allergan to create a company worth $330bn have once again raised fears of disruption for contract research organisations (CRO), although there are reasons to think the deal would be less troublesome than earlier megamergers;
Hanson, Shimadzu combine technologies to create an automated testing system............
Hanson Research and Shimadzu have teamed up to combine their respective technologies into an automated online pharmaceutical testing system;
hVIVO invests in PrEP Biopharm............
hVIVO has made an investment in the UK-based start-up, PrEP Biopharm, to further develop new prophylactic treatment for respiratory infections;
Tara Immuno-Oncology acquires licenses to develop clinical stage p53MVA oncology vaccine............
Tara Immuno-Oncology has acquired licenses from City of Hope for the development of p53MVA (modified vaccinia ankara) and a Salmonella-based therapy targeting Indoleamine 2,3-Dioxygenase (shIDO-ST), both for multiple oncology indication;
p>FDA approves Gilead Sciences' Genvoya HIV drug............
The US Food and Drug Administration (FDA) has approved Gilead Sciences' Genvoya HIV drug to treat patients aged 12 and above;
LEO Pharma to buy Astellas Pharma's global dermatology portfolio............
LEO Pharma has agreed to acquire Astellas Pharma's global dermatology business for €675m;
Emerson, GE Healthcare partner to increase biopharma manufacturing efficiency............
Emerson Process Management has partnered with GE Healthcare’s Life Sciences business to increase productivity and improve efficiency in the production of biopharmaceuticals;
AstraZeneca agrees to sell US rights for Entocort drug to Perrigo............
AstraZeneca has agreed to sell the US rights for its gastrointestinal drug Entocort to Perrigo for $380m;
Acquired Sigma-Aldrich businesses part of Merck's Africa growth plan............
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck;
Online Product Assistant
VIVAN Life Sciences is a Knowledge based and technology driven innovative Global Enterprise, offering higher end products in Pharmaceuticals and Life Sciences.
We provide break through collaboration for the niche pharmaceutical products, which enhance the capability and productivity performances of our customers and Business Associates around the world, In specific functions critical to their success.
Our Esteemed Clientele consists of, Global Pharmaceuticals and Life Sciences Companies, Pharmaceutical Generic companies, CROs (Contract Research Organizations), Clinical Research, Speciality Chemical Companies, Medical Research Organizations, world renowned Research Institutes and Universities.
We are instrumental in providing the higher-end products to our clientele around the world, and played an important role in the success of their Crucial projects.
there by improving and deriving exceptional value to the Projects critical to their success.
Please visit VIVAN BLOG: